Upjohn/Geneva Pharmaceuticals

Executive Summary

Enter marketing agreement for generic versions of two Upjohn products and are negotiating a second agreement covering additional products, Ciba-Geigy subsidiary Geneva announced March 11. The two products covered by the agreement were not named, but the deal is described as part of Upjohn's strategy to reduce the impact of product patent expirations. Top-selling Upjohn products with patents scheduled to expire in the next few years include: Micronase (glyburide -- April 1992); Ansaid (flurbiprofen -- February 1993); Xanax (alprazolam -- September 1993); and Halcion (triazolam -- September 1993).